Squarepoint
CYTK icon

Squarepoint’s Cytokinetics CYTK Stock Holding History

Squarepoint’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,500
Closed -$494K – 4740
2024
Q4 		$494K Buy
10,500
+6,200
+144% +$322K ﹤0.01% 3730
2024
Q3 		$227K Sell
4,300
-4,300
-50% -$240K ﹤0.01% 3614
2024
Q2 		$466K Buy
+8,600
New +$519K ﹤0.01% 3127

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint's CYTK Position: Q2 2026 in Review

Squarepoint opened a new position in Cytokinetics (CYTK) in Q2 2026: 2,655 shares worth $226K. The stake represents ﹤0.01% of the portfolio and ranks #3992 among its holdings. This is a return to the name: Squarepoint previously reported a position in CYTK as recently as Q3 2025.

Squarepoint first reported a position in CYTK in Q1 2016 and has held it in 28 quarters since. The position peaked at $5.78M in Q3 2025. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Squarepoint held 2,655 shares of Cytokinetics worth $226K as of Q2 2026.
  • Cytokinetics was a new Squarepoint position in Q2 2026.
  • Cytokinetics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3992 holding.
  • Squarepoint first reported a position in Cytokinetics in Q1 2016 and has held it in 28 quarters since.
  • Squarepoint's Cytokinetics position peaked at $5.78M in Q3 2025.
  • 483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.